Effect of daclizumab, tacrolimus, and mycophenolate mofetil in pediatric first renal transplant recipients.
Ciancio
Gaetano
G
Department of Surgery, Division of Transplantation, University of Miami School of Medicine, Highland Professional Building 5th Floor, 1801 NW 5th Avenue, Suite 517, Miami, FL 33136, USA. gciancio@med.miami.edu
Burke
G W
GW
Suzart
K
K
Mattiazzi
A
A
Rosen
A
A
Zilleruello
G
G
Abitbol
C
C
Montane
B
B
Miller
J
J
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002648:Child; D002675:Child, Preschool; D000077561:Daclizumab; D004359:Drug Therapy, Combination; D005260:Female; D005431:Florida; D005500:Follow-Up Studies; D006650:Histocompatibility Testing; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007518:Isoantibodies / Q000097:blood; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D044469:Racial Groups; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D007518:Isoantibodies; D000077561:Daclizumab; D009173:Mycophenolic Acid; D016559:Tacrolimus